Form 4 for ANAB ANAPTYSBIO, INC
Accepted 2025-12-18 00:00:00 ET · period of report 2025-12-16 · accession 0001239648-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-18 | 2025-12-16+ | ANAB | LOUMEAU ERIC J | CLO | M - OptEx | $16.07 | +22.5K | 19.1K | New | +$361.5K |
| DM | 2025-12-18 | 2025-12-16+ | ANAB | LOUMEAU ERIC J | CLO | S - Sale+OE | $45.38 | -22.6K | 8,947 | -72% | -$1.03M |
| DM | 2025-12-18 | 2025-12-16+ | ANAB | LOUMEAU ERIC J | CLO | M - OptEx | $0.00 | -22.5K | 53.0K | -30% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-16 | M | A | 7,500 | $20.16 | 21,588 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-16 | S | D | 8,305 | $44.68 | 13,283 | D | — | — | (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.12 to $45.11 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2025-12-16 | S | D | 4,195 | $45.24 | 9,088 | D | — | — | (F3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.13 to $45.34 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2025-12-17 | S | D | 10,000 | $46.00 | 9,088 | D | — | — | |
| 5 | Common | Common Stock | 2025-12-18 | S | D | 141 | $46.99 | 8,947 | D | — | — | |
| 6 | Common | Common Stock | 2025-12-16 | M | A | 5,000 | $14.02 | 14,088 | D | — | — | |
| 7 | Common | Common Stock | 2025-12-17 | M | A | 10,000 | $14.02 | 19,088 | D | — | — | |
| 8 | Derivative | Employee Stock Option (right to buy) | 2025-12-16 | M | D | 5,000 | $0.00 | 63,000 | D | $14.02 · — to 2029-12-05 | 5,000 Common Stock | (F4) The stock option is fully vested. |
| 9 | Derivative | Employee Stock Option (right to buy) | 2025-12-16 | M | D | 7,500 | $0.00 | 0 | D | $20.16 · — to 2030-07-12 | 7,500 Common Stock | (F4) The stock option is fully vested. |
| 10 | Derivative | Employee Stock Option (right to buy) | 2025-12-17 | M | D | 10,000 | $0.00 | 53,000 | D | $14.02 · — to 2029-12-05 | 10,000 Common Stock | (F5) In addition to the options to purchase a total of 53,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 414,810 shares of common stock, which options vest according to their terms. (F4) The stock option is fully vested. |